International Cancer Research Partnership |

International Collaboration to Advance Global Cancer Research: The US National Cancer Institute Perspective

Read more about International Collaboration to Advance Global Cancer Research: The US National Cancer Institute Perspective

November 20, 2020 8:30 AM (EST) - November 20, 2020 9:30 AM (EST)

https://www-cms.cancer.gov/about-nci/organization/cgh/events/lgcw-2020

Friday, November 20, 2020, 8:30 AM ET

The aim of this virtual webinar is to showcase examples of global cancer research partnerships and collaborations from the US National Cancer Institute perspective. The session will start with an overview of the new mission, vision, and goals of the US National Cancer Institute Center for Global Health as laid out by Director Satish Gopal, MD, MPH. The session will include unique viewpoints on building global cancer research collaborations as outlined by NIH-funded cancer researchers and trainees from different regions of the world. The presentations will highlight different aspects of partnership-building to advance global cancer research, lessons learned, and recommendations. The session will conclude with a discussion and audience question and answer period. For additional information about this event, please click here.

Webinar

The Evolving Global Tobacco Epidemic

Read more about The Evolving Global Tobacco Epidemic

November 16, 2020 11:00 AM (EST) - November 16, 2020 12:00 PM (EST)

https://www.fredhutch.org/en/events/global-oncology-lecture-series-november-16-2020.html

November 16, 2020, 11:00 AM ET

CGH Branch Chief Dr. Mark Parascandola will serve as keynote speaker of the Fred Hutch Global Oncology Virtual Lecture Series Exit Disclaimer. He will present “The Evolving Global Tobacco Epidemic.” While tobacco use is declining in most high-income countries, the burden is shifting to low- and middle-income countries where over 80% of tobacco users now reside. Smoking prevalence remains comparatively low in some regions, such as sub-Saharan Africa, but is projected to increase with increased economic development and tobacco industry marketing. The WHO Framework Convention on Tobacco Control (FCTC) has provided a legal mechanism to advance evidence-based tobacco control policies in countries around the world. However, implementation of the FCTC remains far from complete. The global tobacco epidemic continues to pose a critical public health challenge in the face of changing circumstances, including the introduction of e-cigarettes and the COVID pandemic.

Webinar

Advancing the Field of Academic Global Oncology: Perspectives from the US NCI Global Oncology Survey of NCI-Designated Cancer Centers

Read more about Advancing the Field of Academic Global Oncology: Perspectives from the US NCI Global Oncology Survey of NCI-Designated Cancer Centers

November 5, 2020 1:00 PM (EST) - November 5, 2020 3:00 PM (EST)

https://aspo.org/training_resource/advancing-the-field-of-academic-global-oncology-perspectives-on-research-topics-geographical-diversity-and-funding-support-from-the-us-nci-global-oncology-survey-of-nci-designated-cancer-centers/

Advancing the Field of Academic Global Oncology: Perspectives from the US NCI Global Oncology Survey of NCI-Designated Cancer Centers

November 5, 2020, 1:00 PM ET

The American Society of Preventive Oncology's Global Cancer Research Special Interest Group is hosting the upcoming webinar: Advancing the Field of Academic Global Oncology: Perspectives from the US NCI Global Oncology Survey of NCI-Designated Cancer Centers Exit Disclaimer, featuring speakers from NCI’s Center for Global Health and Johns Hopkins Bloomberg School of Public Health.

Webinar

ESMO Asia 2020

Read more about ESMO Asia 2020

November 20, 2020 6:00 AM (EST) - November 22, 2020 8:00 AM (EST)

https://www.esmo.org/meetings/esmo-asia-2020-virtual/registration

Webinar

Skin cancer awareness week (Australia)

Read more about Skin cancer awareness week (Australia)

November 15, 2020 6:00 AM (EST) - November 21, 2020 8:00 AM (EST)

Twitter Promotional Event

Pancreatic cancer awareness month

Read more about Pancreatic cancer awareness month

November 1, 2020 6:00 AM (EST) - November 30, 2020 8:00 AM (EST)

Twitter Promotional Event

Stomach Cancer Awareness Month

Read more about Stomach Cancer Awareness Month

November 1, 2020 6:00 AM (EST) - November 30, 2020 8:00 AM (EST)

Twitter Promotional Event

Lung Cancer Awareness month

Read more about Lung Cancer Awareness month

November 1, 2020 6:00 AM (EST) - November 30, 2020 8:00 AM (EST)

#LungCancerAwarenessMonth

Twitter

Twitter Promotional Event

NCRI - Demystifying patient and public involvement in cancer research

Read more about NCRI - Demystifying patient and public involvement in cancer research

November 12, 2020 7:00 AM (EST) - November 12, 2020 8:00 AM (EST)

Online - https://conference.ncri.org.uk/virtual-events-programme/#PPI

Date: Thursday 12 November 2020
Time: 12:00 -13:00 (GMT)
Chair: Emma Kinloch, Chair of NCRI Consumer Forum, UK
Speakers: Alison Fielding, Dave Chuter, Professor Hisham Mehanna, Tim Banks

This session aims to explain the role of patient and public involvement (PPI) in cancer research, why it is important and how you can get involved. Panellists will share their experiences of being a PPI representative (also known as ‘consumers’) or working with PPI representatives. The session aims to highlight the range of different involvement opportunities across the NCRI Partnership and beyond, with a view to encouraging many more people to get involved in cancer research

Webinar

ASTRO Annual Meeting 2020

Read more about ASTRO Annual Meeting 2020

October 22, 2020 4:00 AM (EDT) - October 29, 2020 1:00 PM (EDT)

https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-Meeting

https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-Me…

Annual Meeting Schedule

Thursday, October 22

Virtual Platform Sneak Peak

Friday, October 23

NEW! Exhibit Hall Only Day – 10:00 a.m. - 5:00 p.m. Eastern time

Saturday, October 24 – Thursday, October 29

Full Virtual Platform Available
Exhibit Hall Open Daily 10:00 a.m. - 5:00 p.m. Eastern time

Friday, October 30 – Monday, November 30

Full Virtual Platform Available OnDemand

Conference/Meeting

Single-funder organizations
Partner	Caveat
ACS	Dollar amounts found in the ICRP database are different than what is reported in the American Cancer Society's Annual Report. The dollar amounts spent on research reported in audited reports include operating expenses of the Research Department. Additionally, the dollar amounts also exclude all grants that were cancelled after being awarded, but include money that was returned from grants cancelled in the current year that were awarded in previous years. The dollar amounts reported in the database are unaudited and include grants awarded each fiscal year, exclusive of grants that cancelled before activation.
CBCRP	The California Breast Cancer Research Program grants are awarded only to individuals or institutions in California. Grants to the University of California receive only direct funds, while grants to other institutions also receive indirect costs (overhead) at 25% or the federally negotiated rate. Collaborative awards are counted in graphs and tables by the number of co-Principal Investigators rather than the number of projects.
Komen	Dollar amounts found in the ICRP database are different than what is reported on Komen\'s website or in Komen\'s Annual Report for the following reasons: Komen commits all funds necessary to support a research grant in the year it is awarded. Therefore, Komen\'s website reports on the full amount of each grant in the year it is initiated, while the ICRP data is annualized, as described. Komen funds research grants to our Scientific Advisors (Scientific Advisory Board members and Komen Scholars) and also provides discretionary funding of research-related projects that are not traditional research grants (e.g. support of the Komen Tissue Bank, ASCO and AACR meeting support). These are included in the overall Research Program spending, as reported in our Annual Report and on our website, but are not included in the ICRP database.
NIH	NIH projects in NIH Reporter assigned to the Spend Category ‘cancer’ are included in the ICRP database from FY2005 onwards. A small number of projects are excluded if essential information is missing (primarily Project title, Institution). Previous years’ data were drawn from the NFRP and may be incomplete. Starting in FY2007 NCI reports funding supplements, etc., for each grant separately instead of including them in the main project, therefore the number of projects may differ significantly from those of previous years. Projects with a cost of $0 include those that were a no-cost extension of the grant or when funding was provided by another NIH institute or center for that FY. NCI dollars in the ICRP database are drawn from NIH reporter and may not match dollars from other NCI-only databases.
Worldwide Cancer Research	Worldwide Cancer Research is unique in that the majority of our funding is awarded to researchers in countries outside the UK. Like many UK research charities, Worldwide Cancer Research only funds the direct costs of research. This creates significant problems in making quantitative comparisons between our funding and that provided by some of the other agencies in the ICRP, which fund both the direct and indirect costs (often called overheads) of research.

UK Organizations that are part of NCRI
Partner	Caveat
NCRI (GENERIC)	NCRI submits data to ICRP on behalf of all UK NCRI members from its Cancer Research Database (CaRD). The database only includes entries where funding can be directly attributed to a set of clearly defined research objectives. This means that the CaRD only contains information on all direct research funding (project, programme, fellowship, unit and institute) financed by NCRI Member organizations, for which an abstract has been submitted and where the project is active in any given financial year (April - March). Examples of funding that are currently outside the scope of CaRD are infrastructure, meeting grants and research management support."
Breakthrough (UK)	The ICRP database includes all Breakthrough Breast Cancer\'s research spend reported through its Annual Reports & Accounts. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some research spend that is already committed may not be included in the ICRP figures. Expenditure on non-research charitable activities and management support costs are excluded from the NCRI, and by extension, the ICRP dataset. For further information on Breakthrough\'s research please visit www.breakthroughresearch.org.uk or email research@breakthrough.org.uk
CR-UK (UK)	The ICRP database includes around 70% of Cancer Research UK\'s direct research spend per financial year as reported through its Annual Reports & Accounts. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on vital research services, technology transfer, meeting grants, research management support and infrastructure to support Cancer Research UK\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Department of Health (UK)	There will always be some variance between the figures available on ICRP and the figures reported publicly by DH. There are two reasons for this. Firstly, there is variance due to different reporting periods (1 April snapshot of ICRP versus full financial year reporting by DH). Secondly, the Department\'s National Institute for Health Research (NIHR) encompasses various expenditure on NHS infrastructure for research relevant to cancer that is not in a format that it is possible to capture for ICRP.
Macmillan (UK)	The ICRP database represents about 90% of Macmillan Cancer Support\'s direct research spend per financial year. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on research management support and infrastructure to support Macmillan Cancer Support\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Scottish Government Health Directorates (UK)	Scottish Government is committed to improve the health of the Scottish population and the Chief Scientist\'s Office (CSO) funds across a broad range of relevant disease areas. Overall, 75% of the CSO spend is committed to research infrastructure in NHS Scotland. This and much other research expenditure is therefore outside the NCRI remit and, by extension, the ICRP dataset.

Canadian organizations who are part of the CCRA
Partner	Caveat
CCRA	Caveats/limitations specific to Canadian Cancer Research Alliance organizations can be accessed here.

Difference	Detail	Impact on investment figures
Not all CCRS participating organizations are included in the ICRP.	For the period 2005–2021, CCRA submitted data to the ICRP for 35 organizations and three now defunct multi-funded initiatives (CBCRA, CPCRI, and CTCRI). Note that the Canadian Breast Cancer Research Foundation merged operations with the Canadian Cancer Society in February 2017 and Prostate Cancer Canada merged in 2020. Importantly, Alberta Innovates did not report any research projects for 2020 and 2021 due to staffing constraints. Projects within the CCRS total 30,218, of which 24,129 were reported to ICRP.	Moderate for years 2020 and 2021
Not all CCRS projects are included in the ICRP.	“Related support” grants (i.e., travel awards, workshops/symposia, LOIs, etc.) are not submitted to ICRP, but are included in reports released by CCRA. In addition, equipment/infrastructure grants through the Canada Foundation for Innovation and for other funders where the cancer relevance weighting is less than 80% are not reported to the ICRP, but are included in CCRA reports. Any project with cancer relevance of less than 20% is also not reported to the ICRP.	Moderate
Co-funded projects are listed by the administering organization.	Projects that are co-funded appear under the administering organization and are not duplicated per funder. Within CCRA reports, however, investments are reported by the actual funders.	Minor
ICRP uses a different approach to calculating annual project investment.	CCRA provides ICRP with the project budget (adjusted for cancer relevance) and start and end dates. A pro-rated calculation is used to derive annual investment. Within the CCRS, prorated calculations on the basis of annual project amounts (where those data are available) are used to calculate the annual investment.	Minor
ICRP uses different site coding conventions.	The cancer site/type codes used within the CCRS are different from ICRP site codes so results by site will vary in some instances.	Minor
ICRP has technical limitations.	ICRP has a technical limit of 12 site codes and 8 CSO codes and this requires truncation for a couple of large-scale projects within the CCRS.	Very minor
CCRA provides less descriptive information about its projects to ICRP.	Lay abstracts are submitted by CCRA to the ICRP in lieu of technical abstracts and in their language of origin. For projects without lay abstracts (and there are a significant number of these), only titles are provided. An English translation is provided alongside all French project titles to facilitate use of the search engine.	No impact on investment figures, but limits full functionality of search engine especially for organizations that do not collect/report lay abstracts.